spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

Right arrow Help viewing high resolution images
Right arrow Return to article
(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.


Figure 5


Fig. 5. KRASG12D activates the RAF1/MEK/ERK1/2 and PI3K/AKT pathways in granulosa cells. (A) RAS activity in wild-type ovaries during ovulation, as measured by a GST pull-down assay using RAF1 RAS-binding domain (RBD) as the bait. NT, non-treated. (B) RAS-GTP levels increased in immature LSL-KrasG12D;Amhr2-Cre and LSL-KrasG12D;Cyp19-Cre ovaries, as measured by the GST pull-down assay using both RAF1 RBD and p110{alpha} RBD. (C) Phosphorylation of MEK1/2, ERK1/2 and AKT in wild-type and LSL-KrasG12D;Cyp19-Cre ovaries after eCG/hCG treatment. Total ERK1/2 and AKT are shown as loading controls. (D-F) Localization of phospho-ERK1/2 in ovaries. The level of phospho-ERK1/2 was low in immature wild-type mouse ovaries (D), but was increased in the large antral follicles 2 hours after hCG injection (E). By contrast, the phospho-ERK1/2 level remained low in LSL-KrasG12D;Cyp19-Cre ovaries after the same treatment (F). (G-I) Immunofluorescence of phospho-AKT in wild-type ovaries. (G) Immature ovary; (H) 48 hours after eCG; (I) 2 hours after hCG. (J-L) Immunofluorescence of phospho-AKT in LSL-KrasG12D;Cyp19-Cre ovaries. (J) Immature ovary before eCG treatment (abnormal follicle-like structures indicated by arrows); (K) 48 hours after eCG treatment; (L) 2 hours after hCG treatment. Three to six ovaries from different animals of each genotype were analyzed in each of these experiments.





Right arrow Return to article